Holen Sie sich die Stockscreener-App
24.40
4.95%
1.15
Handel nachbörslich:
25.07
0.67
+2.75%
Schlusskurs vom Vortag:
$23.25
Offen:
$23.49
24-Stunden-Volumen:
1.30M
Relative Volume:
1.17
Marktkapitalisierung:
$2.06B
Einnahmen:
$42.95M
Nettoeinkommen (Verlust:
$-130.01M
KGV:
-14.99
EPS:
-1.6278
Netto-Cashflow:
$-19.66M
1W Leistung:
+0.83%
1M Leistung:
+49.05%
6M Leistung:
+4.81%
1J Leistung:
+390.95%
1-Tages-Spanne:
$23.04
$24.98
1-Wochen-Bereich:
$22.94
$25.22
52-Wochen-Spanne:
$4.12
$25.77
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
Firmenname
Monte Rosa Therapeutics Inc
Sektor
Branche
Telefon
617-949-2643
Adresse
321 HARRISON AVENUE, BOSTON
Compare GLUE vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
24.40 | 1.96B | 42.95M | -130.01M | -19.66M | -1.6278 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.93 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.50 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-02-15 | Eingeleitet | Wedbush | Outperform |
| 2023-01-03 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-10-13 | Eingeleitet | UBS | Buy |
| 2022-08-15 | Eingeleitet | Jefferies | Buy |
| 2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
| 2022-02-10 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-10-14 | Eingeleitet | SVB Leerink | Mkt Perform |
Alle ansehen
Monte Rosa Therapeutics Inc Aktie (GLUE) Neueste Nachrichten
Monte Rosa Therapeutics (NASDAQ:GLUE) Trading Up 6.9%Should You Buy? - MarketBeat
Form 4 Monte Rosa Therapeutics Inc For: 6 July By Investing.com - Investing.com Canada
NEA funds shift 1,000,000 Monte Rosa shares (NASDAQ: GLUE) - Stock Titan
NEA adjusts Monte Rosa Therapeutics (GLUE) stake with share distribution and sales - Stock Titan
GLUEMonte Rosa Therapeutics Inc Volatility & Greeks - Finviz
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Monte Rosa CMO Filip Janku sells $132k in company stock - Investing.com
Filip Janku Sells 5,407 Shares of Monte Rosa Therapeutics (NASDAQ:GLUE) Stock - MarketBeat
Form 4 Monte Rosa Therapeutics Inc For: 1 July By Investing.com - Investing.com India
Monte Rosa Therapeutics (NASDAQ: GLUE) CMO trades 5,407 shares under 10b5-1 plan - Stock Titan
Form 144 Monte Rosa Therapeutics For: 30 June By Investing.com - Investing.com Australia
Form 4 Monte Rosa Therapeutics Inc For: 30 June By Investing.com - Investing.com South Africa
Monte Rosa director Anthony Manning sells $231,100 in GLUE shares By Investing.com - Investing.com Nigeria
GLUE (NASDAQ: GLUE) affiliate reports option exercise and 10b5-1 sales in June 2026 - Stock Titan
Monte Rosa Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Monte Rosa (NASDAQ: GLUE) CMO exercises options, sells 6,000 shares - Stock Titan
Monte Rosa (NASDAQ: GLUE) director exercises options, sells 10,000 shares at $23.11 - Stock Titan
Guggenheim raises Monte Rosa stock price target on pipeline potential - Investing.com UK
Guggenheim raises Monte Rosa stock price target on pipeline potential By Investing.com - Investing.com South Africa
symbol__ Stock Quote Price and Forecast - CNN
After a 400% Surge, Should Investors Care About This $882,000 Monte Rosa Insider Sale? - The Motley Fool
GLUE (NASDAQ: GLUE) option exercise; insider 10b5-1 sales total 41,845 shares - Stock Titan
Anthony Manning sells 10,000 GLUE shares; option exercise planned (GLUE) - Stock Titan
Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell 2500 Growth Benchmark - marketscreener.com
Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell 2000 Value Benchmark - marketscreener.com
Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell 2000 Growth Benchmark - marketscreener.com
Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell 3000E Growth Benchmark - marketscreener.com
Does Monte Rosa Therapeutics' (GLUE) Shift Into Russell Growth Indices Recast Its Biotech Risk Profile? - simplywall.st
Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell 3000E Value Benchmark - marketscreener.com
Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell 2500 Value Benchmark - marketscreener.com
Monte Rosa Therapeutics, Inc. Actuals & Estimates (NASDAQ:GLUE) - TradingView
Monte Rosa (GLUE) CMO sells 41,845 shares after exercising options - Stock Titan
Monte Rosa (NASDAQ: GLUE) COO exercises stock options, sells 2,175 shares - Stock Titan
GLUE Forecast — Price Target — Prediction for 2027 - TradingView
Monte Rosa Therapeutics Inc (GLUE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Insider exercises 30,000 shares; sells 11,845 under 10b5-1 (GLUE) - Stock Titan
Wells Fargo Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Maintains Target Price $29 - Moomoo
Monte Rosa Therapeutics Inc (GLUE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Form 144 MONTE ROSA THERAPEUTICS INC For: 23 June By Investing.com - Investing.com South Africa
Form 144 MONTE ROSA THERAPEUTICS For: 23 June By Investing.com - Investing.com South Africa
GLUE News | MONTE ROSA THERAPEUTICS INC (NASDAQ:GLUE) - ChartMill
Form 144 Monte Rosa Therapeutics For: 23 June By Investing.com - Investing.com Australia
GLUE (NASDAQ: GLUE) insider files Form 144 to sell 11,845 shares on 06/23/2026 - Stock Titan
Finanzdaten der Monte Rosa Therapeutics Inc-Aktie (GLUE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Monte Rosa Therapeutics Inc-Aktie (GLUE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Janku Filip | Chief Medical Officer |
Jun 30 '26 |
Sale |
24.50 |
5,407 |
132,472 |
60,612 |
1.18%
2.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):